Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Rectal Cancer treatment details. Biologic therapy. Chemotherapy. Hospital General Universitario Gregorio Marañón, Madrid, Spain

Survival: 23.7 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: Spain
City/State/Province: Madrid
Hospital: Hospital General Universitario Gregorio Marañón
Journal: Link
Date: 11/2010

This study involved 46 patients with metastatic colorectal carcinoma who had not received prior chemotherapy. The median patient age was 64 years (range of 39-80), and 46% were male.

Patients were treated with a combination of the biologic therapy agent bevacizumab (an antibody that blocks a protein involved in cancer cell growth) and the chemotherapy agents irinotecan and capecitabine.

The maximum reported toxicity level was grade 4. Grade 3/4 adverse events included alopecia (in 13% of patients), asthenia (weakness, 7%), diarrhea (7%), and nausea (9%).

The median progression-free survival for this study was 12.3 months. The median overall survival was 23.7 months.

This study was supported by Roche, makers of bevacizumab (brand name: Avastin).

Correspondence: Dr P Garcia-Alfonso; email:

E-mail to a Friend Email Physician More Information